The pathophysiology of PASC is described right from the initiation of the novel SARS-CoV-2 infection by primordial hijacking of host cellular metabolic machinery, subsequent progression of virus-induced human metabolic reprogramming/dysregulation (HMRD) in a susceptible host, subjecting the patient through a crucial tri-phasic symptomatic clinical onset of COVID-19 (lasting from 34 weeks), and ultimate transition of a survivor into PASC or long-COVID, a virus-free state, lingering with earlier and/or new onset disease manifestations resulting from pre-acquired HMRD (lasting for weeks to months)
Not approved for human use, not for therapeutic applications, and not for in vivo studies in humans
Med Oncol
Divided into three groups, participants received oral supplementation of GSH (250 mg/d), GSSG (250 mg/d), or a placebo for 12 weeks
Your provider may adjust your schedule based on your treatment plan
The role of excitotoxicity in organophosphorous nerve agents central poisoning